EQB announces voting results of annual general meeting of shareholders
The results of the vote for director elections are as follows:
Nominee | Votes For | % For | Votes Withheld | % Withheld |
18,573,097 | 99.74 | 48,046 | 0.26 | |
18,027,947 | 96.81 | 593,196 | 3.19 | |
18,503,485 | 99.37 | 117,658 | 0.63 | |
Yongah Kim | 18,567,490 | 99.71 | 53,653 | 0.29 |
18,576,965 | 99.76 | 44,178 | 0.24 | |
17,971,551 | 96.51 | 649,592 | 3.49 | |
18,451,697 | 99.09 | 169,446 | 0.91 | |
18,516,204 | 99.44 | 104,939 | 0.56 | |
18,600,644 | 99.89 | 20,499 | 0.11 | |
18,599,817 | 99.89 | 21,326 | 0.11 |
Final voting results on all matters voted on at the Meeting will be published on EQB's Investor Relations website under Annual Reports and filed with the Canadian securities regulators.
About EQB Inc.
EQB Inc. (TSX: EQB) is a leading digital financial services company with
To learn more, please visit eqb.investorroom.com or connect with us on LinkedIn.
Investor contact:
Lemar Persaud
VP and Head of IR
[email protected]
Media contact:
Director, PR & Communications
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eqb-announces-voting-results-of-annual-general-meeting-of-shareholders-302737484.html
SOURCE EQB Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
- Global Health Congress 2026 Convenes Health System Leaders, Clinicians, Technologists, Investors and Innovators at the Yale Club of New York City, October 9th-11th
- Vector Science and Therapeutics Corp. Issues Options
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share